Prospects and possible pitfalls of a preventive Polypill: Confessions of a health promotion convert

European Journal of Clinical Nutrition

Volumn 59, Issue SUPPL. 1, 2005, Pages

  Green, L W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIETARY INTAKE; HEALTH EDUCATION; HEALTH HAZARD; HEALTH PROMOTION; HUMAN; LIFESTYLE; NICOTINE REPLACEMENT THERAPY; NUTRITIONAL HEALTH; PHYSICAL ACTIVITY; POLYPHARMACY; PRESCRIPTION; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; STROKE;

AGED; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; FEMALE; FOLIC ACID; HEALTH PROMOTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; MALE; MIDDLE AGED; PRIMARY PREVENTION; RISK FACTORS;

NICOTIANA TABACUM;

EID: 23944459566     PISSN: 09543007     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602167     Document Type: Article

References (22)

1. Brass EP (2004): Consumer behavior in the setting of over-the-counter statin availability: lessons from the consumer use study of OTC Mevacor. Am. J. Cardiol. 94 (Suppl 9A), 22F-29F.
2. Buchanan DR (2000): An Ethic for Health Promotion: Rethinking the Sources of Human Well-Being. New York, Oxford: Oxford University Press, p 109.
3. Cook NR, Chae C, Mueller FB, Landis S, Saks AM & Hennekens CH (1999): Mis-medication and under-utilization of aspirin in the prevention and treatment of cardiovascular disease. Med. Gen. Med. 1999, E1.
4. David H (1992): The pill is good for you. Entre Nous Cph Den. 20, 11.
5. First International Conference on Health Promotion (1986): The Ottawa Charter for Health Promotion. Health Prom. Int. 1, i-v.
6. Green LW, Eriksen MP, Bailey L & Husten C (2000a): Achieving the implausible in the next decade: tobacco control objectives. Am. J. Public Health 90, 337-339.
7. Green LW, Pappas A, Eriksen M & Fishburn B (2000b): Le role de la legislation dans la lutte contre le tabagisme aux Etats-Unis (Tobacco control legislative experience in the United States). Prom. Educ.: Int. J. Health Prom. Educ. 7, 38-42.
8. Jeffreys D (2004): Aspirin: the Remarkable Story of a Wonder Drug. New York and London: Bloomsbury.
9. INSO Corporation (1996): American Heritage Dictionary of the English Language 3rd Editon, New York: Houghton Mifflin Company. Electronic version licensed from INSO Corporation.
10. Kunkel HO (1996): Interests and values in the Recommended Dietary Allowances and nutritional guidelines for Americans. J. Nutr. 126 (Suppl 9), 2390S-2397S.
11. Law MR, Wald NJ, Morris JK & Jordan RE (2003): Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326, 1427.
12. Law MR, Wald NJ & Rudnicka AR (2003): Quantifying effects of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326, 1423.
13. Mulrow C & Kussmaul W (2005): The middle-aged and older American: wrong prototype for a preventive Polypill? Ann. Intern. Med. 142, 467-468.
14. Nash DB & Nash SA (2004): Reclassification of simvastatin to over-the-counter status in the United Kingdom: a primary prevention strategy. Am. J. Cardiol. 94, 35F-39F.
15. Pearson TA (ed) (2004): Expanding primary prevention efforts: allowing consumers access to over-the-counter statins. Am. J. Cardiol. 94, 1F-39F.
16. Platt L, Hickman M, Rhodes T, Mikhailova L, Karavashkin V, Vlasov A, Tilling K, Hope V, Khutorksoy M & Renton A (2004): The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage. Addiction 99, 1430-1438.
17. Robertson LS (1998): Causal webs, preventive brooms, and housekeepers. Soc. Sci. Med. 46, 53-58.
18. Rosen G (1993): A History of Public Health Expanded Edition Baltimore and London: The Johns Hopkins University Press. p 164.
19. Smith R (2003): The most important BMJ for 50 years? (Editor's choice). BMJ 326, 0.
20. Vasan RS, Sulllivan LM, Wilson PW, Sempos CT, Sundstrom J, Kannel WB, Levy D & Apostino RB (2005): Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann. Intern. Med. 142, 393-402.
21. Volpe M, Alderman MH, Furberg CD, Jackson R, Kostis JB, Laragh JH, Psaty BM & Ruilope LM (2004): Beyond hypertension toward guidelines for cardiovascular risk reduction. Am. J. Hypertens. 17, 1068-1074.
22. Wald NJ & Law MR (2003): A strategy to reduce cardiovascular disease by more than 80%. BMJ 326, 1419-1424. (Erratum in: BMJ 37, 586).